NascaCell and Capsulution start joint development program

Novel development for target validation, drug discovery and therapy


NascaCell Technologies AG and Capsulution Nanoscience AG signed a joint development and license option agreement. As part of this joint development program, NascaCell and Capsulution will develop innovative solutions for improved delivery of aptamers and other nucleic acids into cells. The joint development shall benefit from the combination of advanced nano-technologies and efficient transport peptides and shall generate innovative, target-specific delivery systems for biomolecules into cells and experimental animals.

Specifically, the partners will couple aptamers to functional peptide nanoparticles with subsequent analyses in cellular assays as well as animal studies. The nano-particles and -capsules are also suitable to deliver drug development candidates and will be optimized in this direction.

"We expect additional growth of our aptamer service business, in particular for intracellular applications, from this combination of our gene transfer know how and Capsulution`s established formulation expertise. Furthermore, these new methods will also be applicable for other applications such as therapeutic RNAi. Capsulution with an established track record of its innovative technology is an ideal partner in this endeavour," says Dr. Ernst Boehnlein, CEO of NascaCell.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances